US EditionResearch to Watch: FDA Grants ZL-1310 Fast Track Designation for Extensive-Stage SCLC - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Research to Watch: FDA Grants ZL-1310 Fast Track Designation for Extensive-Stage SCLC - ILCN.org (ILCN/WCLC)
The US Food and Drug Administration (FDA) has granted Fast Track Designation to ZL-1310 for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This decision underscores the ongoing need to develop new therapies for patients with small cell lung cancer (SCLC) and marks an important step forward in clinical progress. The designation is based on updated results from an ongoing phase 1a/1b trial, which were presented at the 2025 Amer…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
